Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)

Trial Profile

A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Dec 2018 Planned primary completion date changed from 11 Dec 2018 to 11 Mar 2019.
    • 01 Nov 2018 Planned primary completion date changed from 11 Oct 2018 to 11 Dec 2018.
    • 15 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top